NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 2.76 against a street estimate of 1.00 — a beat of 176.0%.
with an average price target of ₹300.00.
| Document | Date |
|---|---|
| Annual report FY2026 | 2026-08-31 |
| Q1 FY27 earnings call HIKAL LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 FY27 Revenue: Rs 403 crores • Q1 FY27 EBITDA: Rs 37 crores at 9.2% margin • Q1 FY27 P | 2026-08-12 |
| Investor presentation · Q1 FY27 HIKAL LIMITED – Q1 FY27 INVESTOR SUMMARY --- HEADLINE NUMBERS • Q1 FY27 Consolidated Revenue: ₹403 Crores (up 5.9% YoY from ₹380 Cr in Q1 FY26; dow | 2026-08-06 |
| Quarterly results · Q1 FY27 HIKAL LIMITED – Q1 FY2026-27 FINANCIAL SUMMARY HEADLINE NUMBERS • Total Revenue from Operations (Q1 FY27): Rs 4,028 million, down 22.4% YoY from Rs | 2026-08-06 |
| Q4 FY26 earnings call HIKAL LIMITED - Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY26 Revenue: INR 519 crores | EBITDA: INR 105 crores | EBITDA Margin: 20.3% | PAT: I | 2026-06-03 |
| Investor presentation · Q4 FY26 HIKAL LIMITED – FY26 INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue: Rs. 1,713 crores (down 8% from Rs. 1,860 crores in FY25) • FY26 EBITDA: Rs. 2 | 2026-05-27 |
| Quarterly results · Q4 FY26 HIKAL LIMITED – DOCUMENT SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Full Year (FY 2025-26) Revenue: ₹17,126 million (down 7.9% from ₹18,598 mil | 2026-05-27 |
| Quarterly results | 2026-04-13 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹0.40 / share ex-date Sep 4, 2026 | 2026-09-04 |
| Dividend | ₹0.20 / share ex-date Feb 17, 2026 | 2026-02-17 |
| Dividend | ₹0.80 / share ex-date Sep 2, 2025 | 2025-09-02 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Hikal Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.